|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.75 EUR | +0.19% |
|
+2.09% | +17.51% |
| Dec. 04 | Grifols achieves self-sufficiency in plasma-derived medicines in Egypt | RE |
| Dec. 03 | European Equities Traded in the US as American Depositary Receipts Higher in Wednesday Trading | MT |
Business description: Grifols, S.A.
- products derived from plasma (85.2%): products for use by the pharmaceutical and biotechnology industries;
- diagnostic machines and reagents (8.9%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers;
- hospital products (3%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies;
- other (2.9%): primarily intermediate biological products and subcontracted manufacturing services.
Net sales are distributed geographically as follows: Spain (5.9%), European Union (15.5%), the United States and Canada (56.7%) and other (21.9%).
Number of employees: 23,800
Sales by Activity: Grifols, S.A.
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
Biopharma | 4.24B | 3.81B | 5.01B | 5.56B | 6.14B |
Bio Supplies | 224M | 226M | 146M | 160M | 216M |
Diagnostic | 776M | 779M | 671M | 670M | 645M |
Others | 31.99M | 39.62M | 250M | 203M | 209M |
Intersegments | -53.11M | -67.55M | -8.95M | - | - |
Hospital | 119M | 141M | - | - | - |
Geographical breakdown of sales: Grifols, S.A.
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
United States + Canada | 3.6B | 3.15B | 3.86B | 3.9B | 4.09B |
Rest of the World | 906M | 872M | 1.18B | 1.44B | 1.58B |
Rest of European Union | 495M | 544M | 712M | 893M | 1.12B |
Spain | 339M | 362M | 321M | 363M | 423M |
Executive Committee: Grifols, S.A.
| Manager | Title | Age | Since |
|---|---|---|---|
Nacho Abia
CEO | Chief Executive Officer | 57 | 2024-03-31 |
Jörg Schüttrumpf
CTO | Chief Tech/Sci/R&D Officer | 51 | 2024-08-31 |
| Comptroller/Controller/Auditor | 46 | 2015-12-31 | |
| Corporate Officer/Principal | 55 | 2018-12-31 | |
David Bell
LAW | General Counsel | 71 | 2003-06-30 |
Composition of the Board of Directors: Grifols, S.A.
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 75 | 2010-01-24 | |
| Director/Board Member | 69 | 2000-04-12 | |
| Director/Board Member | 62 | 2015-05-23 | |
| Director/Board Member | 49 | 2016-05-26 | |
| Director/Board Member | 60 | 2019-05-23 | |
| Director/Board Member | 57 | 2022-06-09 | |
| Director/Board Member | 48 | 2022-06-09 | |
Albert Coma-Cros
BRD | Director/Board Member | 47 | 2023-12-18 |
| Director/Board Member | 60 | 2015-05-28 | |
Nacho Abia
BRD | Director/Board Member | 57 | 2024-02-25 |
Holdings: Grifols, S.A.
| Name | Equities | % | Valuation |
|---|---|---|---|
| 437,069,656 | 6.49% | 414,962,673 $ |
Company details: Grifols, S.A.
Group companies: Grifols, S.A.
| Name | Category and Sector |
|---|---|
Gri-Cel SA
 Gri-Cel SA Provides investment services | |
Grifols India Healthcare Pvt Ltd. | |
Grifols India Healthcare Pvt Ltd. |
Biopharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.19% | +2.09% | +23.05% | -2.27% | 7.59B | |
| -0.61% | -7.92% | -6.45% | -4.91% | 73.7B | |
| -0.81% | -1.18% | -34.65% | -38.63% | 58.94B | |
| +3.17% | +2.91% | +33.60% | +245.77% | 54.7B | |
| -2.32% | +64.10% | +64.10% | +64.10% | 51.57B | |
| -0.37% | -0.43% | +13.84% | -38.07% | 26.6B | |
| -1.66% | -2.23% | +144.36% | +231.53% | 20.25B | |
| +2.05% | -1.86% | +36.84% | +21.93% | 20.13B | |
| -12.04% | -14.35% | +46.78% | +1,041.25% | 16.58B | |
| -1.50% | +2.26% | +176.22% | +703.05% | 14.19B | |
| Average | -1.39% | -2.26% | +49.77% | +222.37% | 34.43B | |
| Weighted average by Cap. | -0.76% | -2.40% | +29.37% | +132.02% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GRF Stock
- Company Grifols, S.A.
Select your edition
All financial news and data tailored to specific country editions
